Regarding many of the other mutations and translocations that I spoke about, including HER2/neu, BRAF V600E, NTRK
mutations—all of these need a lot of work to determine what would be a very good and, hopefully, less toxic therapy for many of these patients.
What do you hope community oncologists took away from your talk?
First and foremost, I would like for people to be aware that there are different molecular targets that do occur in NSCLC. I hope that it prompts them to test for those molecular abnormalities. Up to approximately 25% of patients with NSCLC can harbor a targetable mutation. I also hope that they realize that many of these molecular targets have not been fully worked out; there are a lot of resistance mechanisms that can develop. Also, I hope that they send patients for clinical trials.